Chronic Pain
Chronic pain is increasingly recognised as a multifaceted condition that may respond to psychedelic therapies, which are gaining attention in clinical settings for their potential efficacy in pain management. Recent research indicates that compounds such as psilocybin and MDMA are entering clinical trials aimed at exploring their therapeutic effects on chronic pain syndromes.
Key Insights
- 1
Psychedelic therapies are being explored as adjuncts to standard treatments for chronic pain, showing promising initial results.
- 2
Psilocybin and MDMA have advanced to clinical trials, demonstrating safety and potential efficacy in specific chronic pain conditions.
- 3
Research suggests that psychedelics may facilitate improved mental health outcomes, potentially enhancing pain tolerance and reducing the perception of pain.
What is Chronic Pain?
Chronic pain is a complex and often debilitating condition characterised by persistent pain lasting longer than the usual course of acute illness, often exceeding three months. It can arise from various underlying pathological conditions, including injury, inflammation, and nerve damage.
The pathophysiology of chronic pain involves alterations in the nervous system, including central sensitisation, where the nervous system becomes hyper-responsive to stimuli, leading to the amplification of pain signals. Symptoms can include not only physical discomfort but also psychological effects such as anxiety and depression.
Chronic pain conditions can manifest in various forms, including neuropathic pain, fibromyalgia, and chronic lower back pain, each requiring tailored treatment approaches. Patients often report reduced quality of life due to the constant discomfort and associated emotional distress.
Current Treatments
Standard treatments for chronic pain generally include pharmacological options such as nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, antidepressants, and physical therapy, alongside psychological therapies like cognitive behavioural therapy (CBT).
Psychedelic Effect Matrix
Compound efficacy and evidence levels for Chronic Pain.
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| Psilocybin Multiple clinical trials have shown significant pain reduction in conditions like neuropathic pain and fibromyalgia. | Large | High | Consistent |
| MDMA Preliminary studies suggest MDMA can provide relief by addressing psychological components of chronic pain. | Medium | Moderate | Consistent |
| Ketamine Widely recognised for its rapid effects on pain relief, particularly in treatment-resistant chronic pain conditions. | Large | High | High |
Psilocybin and Chronic Pain
Clinical studies have also highlighted psilocybin’s potential to reduce rumination and anxiety levels, improving patients’ quality of life and pain thresholds. Positive outcomes have been observed in patients coping with cancer-related pain and other chronic pain syndromes.
MDMA and Chronic Pain
Emerging evidence suggests MDMA may reduce anxiety levels and improve coping mechanisms, thereby alleviating the pain experience. Trial results indicate a promising role for MDMA as part of a holistic treatment approach for chronic pain.
Clinical Outlook
There is an optimistic future for the incorporation of psychedelics into chronic pain management, with ongoing research potentially reshaping therapeutic frameworks. As more clinical trials are conducted, a deeper understanding of the mechanisms through which psychedelics alleviate pain may lead to innovative treatment protocols in pain management.
Industrial Landscape
Key players in psychedelic research for chronic pain include academic institutions like Johns Hopkins University, non-profit organisations focusing on psychedelic therapy, and various pharmaceutical companies investing in psychedelic drug development.
Quick Indicators
Related Topics
Organisations
Search →COMPASS Pathways
COMPASS Pathways is a UK-listed biopharmaceutical company developing COMP360 synthetic psilocybin therapy for treatment-resistant depression, with two successful Phase 3 trials making it the leading candidate for the first regulatory approval of a classic psychedelic medicine.
National Institute of Mental Health (NIMH)
U.S. federal institute defining mental-health research agendas and evidence-generation priorities including psychedelic-relevant studies.
AtaiBeckley
Clinical-stage psychedelic company that also functions as a strategic-corporate capital allocator through legacy atai platform investments and deal activity in the sector.
MAPS
Nonprofit organizer and host of the Psychedelic Science conference series, alongside broader educational and policy programming.
Ceruvia Lifesciences
Ceruvia Lifesciences is a US-based clinical-stage biopharmaceutical company founded in 2017 by philanthropist Carey Turnbull, focused on developing neurotransformational medicines for neurological and psychiatric disorders. The company was the world's first producer of cGMP-certified LSD and its non-hallucinogenic analogue BOL-148. Ceruvia is advancing SYNP-101 (synthetic psilocybin) through Phase 2 trials for OCD, alcohol use disorder, and migraine/headache disorders, and NYPRG-101 (BOL-148) for cluster headache. Collaborators include Yale University, the Heffter Research Institute, Usona Institute, NYU, and Clusterbusters.
University of Amsterdam
The University of Amsterdam (UvA) is one of the Netherlands' leading research universities, with its Amsterdam UMC Department of Psychiatry conducting clinical trials on psilocybin and psychedelic-assisted therapies for treatment-resistant mental health conditions.
Ketamine Research Institute
The Ketamine Research Institute is a US-based clinical research organization developing precision medicine approaches to ketamine infusion therapy, studying optimized dosing protocols to treat depression and offering clinician training in evidence-based ketamine practice.
Portland Psychotherapy
Portland Psychotherapy is a Portland, Oregon clinic, research, and training center that integrates psychedelic science into evidence-based clinical practice, conducting clinical trials of MDMA-assisted therapy for social anxiety disorder and offering psychedelic integration services. Their distinctive model funds peer-reviewed research through clinical revenue, resulting in exceptionally well-trained therapists in psychedelic-assisted care.
Imperial College London
The Centre for Psychedelic Research, led by Professor David Nutt and Dr. David Erritzoe, focuses heavily on the action of psychedelic drugs in the brain and their clinical utility as aides to psychotherapy. Thanks to their extensive neuroimaging studies, this group has proposed vital mechanisms for how psychedelics work, including the Entropic Brain Theory and REBUS (RElaxed Beliefs Under Psychedelics).
Columbia University
Research with psychedelics has been taking place at Columbia University in New York since 2014. Researchers from various departments at the university including Medicine, Psychology and Psychiatry have conducted numerous trials investigating the effects ketamine has on substance use disorders. Some research exploring the anti-depressant effects of ketamine has also taken place. More recently, Columbia University served as a test site for COMPASS Pathway's COMP360 trial which explored the effects of psilocybin on treatment-resistant depression. Professor of Clinical Psychiatry, Dr David Hellerstein served as the principal investigator at this study site.
University of California Davis
The Institute for Psychedelics and Neurotherapeutics (IPN) at UC Davis explores the neuroscience of psychedelics. Under the lead of David Olson, the team conducts high-impact interdisciplinary psychedelic science using modern neurobiology and chemistry tools. Contributions by the group include discovering that psychedelics promote neural plasticity, developing a biosensor for measuring hallucinogenic potential, and designing non-hallucinogenic psychedelic analogues with therapeutic potential.
University of Basel
The University of Basel Department of Biomedicine hosts the Liechti Lab research group, headed by Matthias Liechti. Research here is primarily focused on the pharmacology of psychoactive substances. Much of the clinical research exploring the effects of LSD is taking place at University Hospital Basel. Researchers here are exploring the potential of LSD to treat Cluster Headache, Major Depressive Disorder and anxiety associated with severe somatic diseases. Professor Liechti is also conducting studies comparing the acute effects of LSD, psilocybin and mescaline, and MDMA for fear extinction.
People
Search →Robin Murphy
Researcher at the University of Auckland School of Pharmacy
She is a coauthor on multiple human psychedelic studies spanning LSD microdosing, sleep, and psilocybin/escitalopram comparisons, making her part of the team contributing to the modern evidence base for psychedelic medicine.
Jeanine Kamphuis
Psychiatrist and researcher at the Department for Mood Disorders, University Hospital Groningen (UMCG)
She studies ketamine, esketamine, and classic psychedelics for treatment-resistant psychiatric disorders, including depression, and is a coauthor on multiple psychedelic/ketamine reviews and clinical studies.
Joost Breeksema
Postdoctoral researcher and Executive Director of the OPEN Foundation
He is a prominent psychedelic researcher and advocate whose work helps shape evidence-based psychedelic policy, ethics, and patient-centered understanding of psychedelic and ketamine/esketamine treatments.
Mathieu Seynaeve
Senior Medical Director and Head of Psychotherapy at Beckley Psytech
He is a clinical development leader behind multiple human studies of 5-MeO-DMT and psilocybin, including trials in alcohol use disorder, treatment-resistant depression, and headache disorders.
Kayla Teopiz
Researcher in psychiatry and ketamine/psychedelic medicine research; likely affiliated with the University of Toronto/Trillium Health Partners research network
Teopiz coauthors multiple systematic reviews and clinical studies on ketamine, esketamine, and psilocybin in depression and suicidality, helping synthesize the evidence base for psychedelic and glutamatergic treatments in psychiatry.
Joshua Di Vincenzo
MSc researcher / clinical research staff member at the University Health Network and University of Toronto
He coauthors multiple systematic reviews and real-world studies on ketamine for treatment-resistant depression, making him a visible contributor to the evidence base on psychedelic-adjacent psychiatric therapeutics.
Frederick Sundram
Associate Professor and Deputy Head of the Department of Psychological Medicine at the University of Auckland
He is a psychiatrist and clinical researcher contributing to psychedelic and novel-antidepressant studies, including LSD microdosing and ketamine/depression research.
John Kelly
Associate Professor / Consultant General Psychiatrist at Trinity College Dublin
John R. Kelly is a leading academic psychiatrist in Ireland whose work has helped shape modern psychedelic psychiatry, including psilocybin research across depression, service-user attitudes, and transdiagnostic treatment frameworks.
Valerie Bonnelle
Scientific Assistant to the Director at the Beckley Foundation
She is a researcher coordinating psychedelic studies on microdosing, pain, autonomic physiology, and peak experiences, contributing to the clinical and mechanistic understanding of psychedelic effects.
Yvan Beaussant
Instructor in Medicine at Harvard Medical School and palliative care physician at Dana-Farber Cancer Institute
He is a leading clinical researcher in psychedelic-assisted therapy for serious illness, especially cancer-related depression, demoralization, and existential distress.
Kruti Joshi
Employee at Janssen Scientific Affairs, LLC
Joshi appears to be a Janssen-affiliated researcher coauthoring multiple real-world evidence studies on esketamine access, barriers, utilization, and economic outcomes in treatment-resistant depression.
Marta Valle
PhD; researcher/lecturer in Pharmacology, Therapeutics and Toxicology at Universitat Autònoma de Barcelona and associated researcher at Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau
She is a key clinical psychopharmacology researcher on human ayahuasca studies, including neurophysiology, pharmacokinetics, and potential therapeutic effects on mindfulness and emotion regulation.
Connected Evidence
The latest clinical data and verified academic findings associated with Chronic Pain.